HK inno.N’s IPO price set at top end with record demand for Kosdaq listing

Bookbuilding was 1,871 times oversubscribed, highest for a listing on the Kosdaq, attracting $533 bn

HK inno.N's top-selling CONDITION hangover remedy
HK inno.N's top-selling CONDITION hangover remedy
Jin-seong Kim 1
2021-07-28 19:12:21 jskim@hankyung.com
IPOs

HK inno.N Corp. (inno.N), a pharmaceuticals unit of South Korea's Kolmar Korea, set the initial public offering price at the top end of the proposed band as it enjoyed a record-high demand from institutional investors for a Kosdaq-listing during a bookbuilding process.

Inno.N priced its offering at 59,000 won ($51.1) per share, the top end of its indicative price range of 50,000 won and 59,000 won apiece, according to the company on July 28.

The bookbuilding was 1,871 times oversubscribed, the highest for a listing on the country’s junior Kosdaq, attracting 615 trillion won ($532.9 billion) from 1,627 institutional investors at home and abroad during its bookbuilding on July 23 and 26, according to the company. The bookbuilding reported the second highest ratio in the country after SK IE Technology Co. (SKIET), whose shares were 1,882 times oversubscribed during the process.

Most of the institutional investors made aggressive bets, placing bids at the top end of the proposed price band or higher. However, only 13.5% among the investors pledged to hold the shares in the next one to six months after the listing.

Inno.N was set to raise 596.9 billion won through the IPO, while its market capitalization is expected to be at 1.7 trillion won, becoming one of the top 20 companies on the Kosdaq.

Its success in the bookbuilding is expected to draw massive money from retail investors during a public subscription to sell 2.5 million shares on July 29-30.

Inno.N, which is best known for its popular anti-hangover drink CONDITION, has been expanding its business to hospital cosmetics, skin disease treatments, and functional hair products since Kolmar Korea bought the company in 2018. Last year, inno.N posted record-high earnings with 87 billion won in operating profit and 598.4 billion won in revenue.

Write to Jin-seong Kim at jskim@hankyung.com
Jongwoo Cheon edited this article.

HK inno.N poised to bolster S.Korea's IPO lineup in H2

HK inno.N poised to bolster S.Korea's IPO lineup in H2

HK inno.N's top-selling CONDITION hangover remedy HK inno.N Corp., a pharmaceuticals unit of South Korea's Kolmar Korea, is set to go public in early August at a valuation of around 2 trillion won ($1.8 billion).It is looking to raise between 505.8 billion and 596.9 billion won ($448 million-$5

HK inno.N plans 2021 IPO with $1.8 bn valuation

HK inno.N plans 2021 IPO with $1.8 bn valuation

HK inno.N Corp. (inno.N), previously known as CJ Healthcare Co. and now a subsidiary of Kolmar Korea, has initiated the IPO process for listing within 2021. According to the investment banking industry on May 4, inno.N has applied for a preliminary review of its stock market listing by the Kor

(* comment hide *}